Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy
The REFRACT trial is for people with follicular lymphoma that has returned or not improved after initial treatment. This study aims to find better treatments than what is currently available. Patients will be randomly assigned to receive either a new experimental treatment or one of the standard care options. There are three stages, each testing a different new treatment against standard care. The first stage uses a combination of epcoritamab and lenalidomide. The trial will enrol 284 patients over five years, monitoring their response to treatment and tracking their health for up to a decade to identify more effective therapies.
De un vistazo
¿De qué trata este estudio?
The REFRACT trial is a research study designed for people whose follicular lymphoma has either returned after initial treatment or hasn't responded as expected. Follicular lymphoma is a type of slow-growing cancer of the immune system. When the cancer comes back or doesn't react to standard treatment, doctors call it 'relapsed' or 'refractory'.
The main goal of this trial is to see if certain new treatments are better than the standard treatments currently used. To do this, patients will be randomly assigned to either receive one of the new experimental treatments or one of the standard treatments chosen by their doctor. This is a common way to compare treatments fairly. The study will happen in three main rounds, with each round testing a different new treatment on its own against the standard options. In the first round, the experimental treatment is a combination of two drugs, epcoritamab and lenalidomide.
Throughout the study, doctors will closely monitor how patients respond to their assigned treatment, using scans to check for changes in the lymphoma. The study plans to involve 284 patients over five years. After treatment, patients will be followed up yearly for up to 10 years. This long-term monitoring is important to understand the full impact of these new approaches and identify if they offer improved long-term outcomes compared to existing standard care.
Puntos clave
- The trial compares new treatments for follicular lymphoma that has returned or not responded.
- Patients are randomly assigned to either a new experimental drug or standard care.
- The first new treatment being tested is a combination of epcoritamab and lenalidomide.
- Long-term follow-up for up to 10 years will help assess treatment effectiveness.
- Participation could offer access to new treatments, but potential risks and side effects exist.
- Puede retirarse del estudio en cualquier momento.
¿Quién puede ser elegible?
To join the REFRACT trial, you must be 18 years or older and have follicular lymphoma that has either returned or not responded to previous treatment. This must be confirmed by a recent biopsy, and your lymphoma needs to show up on a specific type of scan (PET-CT).
You should also be generally well enough to tolerate treatment, as judged by your doctor, and have received at least one course of a specific type of chemotherapy called 'immunochemotherapy' in the past. Your blood tests and organ functions (like your kidneys and liver) must be within a healthy range.
However, you cannot join if your lymphoma has recently changed into a more aggressive type, or if you've had certain complex treatments like a bone marrow transplant or specific cell therapies (like CAR-T), unless it was a long time ago. Also, if you've already had a drug called lenalidomide, you won't be able to participate. Women of childbearing potential, or their partners, must agree to use effective contraception.
¿Podría este estudio ser adecuado para ti?
Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.
- ¿Tienes 18 años o más?
- Do you have follicular lymphoma that has either come back or not responded to previous treatment?
- Have you had at least one previous course of immunochemotherapy?
- Are you generally well and your organ functions (like kidneys and liver) are fairly healthy?
- Have you NOT had a stem cell transplant, a recent cell therapy (CAR-T), or a drug called lenalidomide before?
¿En qué consiste la participación?
If you decide to take part in the REFRACT trial, you will be randomly assigned to either receive an experimental new treatment or one of the standard treatments. The chance of getting the experimental treatment depends on which stage of the trial you join; in the first stage, it's a 50/50 chance. The experimental treatment in the first stage involves epcoritamab given as an injection under the skin and lenalidomide taken as a pill, typically over 12 cycles, each lasting 28 days. Follow-up appointments and scans will be part of the process to monitor your health and how your lymphoma is responding to treatment. After your treatment period, you will have yearly check-ups for up to 10 years to see how you are doing in the long term, even after the treatment itself has finished.
Riesgos y beneficios potenciales
Locations (25)
- NHS GrampianCódigo postal verificadoAberdeen, United Kingdom· Aún no reclutando
- Belfast Health & Social Care TrustCódigo postal verificadoBelfast, United Kingdom· Aún no reclutando
- University Hospitals Birmingham NHS Foundation TrustCódigo postal verificadoBirmingham, Reino Unido· Aún no reclutando
- Blackpool Teaching Hospitals NHS Foundation TrustCódigo postal verificadoBlackpool, United Kingdom· Aún no reclutando
- Cambridge University Hospitals NHS Foundation TrustCódigo postal verificadoCambridge, Reino Unido· Aún no reclutando
- Cardiff and vale University LHBCódigo postal verificadoCardiff, Reino Unido· Aún no reclutando
- University Hospitals Coventry and Warwickshire NHS TrustCódigo postal verificadoCoventry, United Kingdom· Aún no reclutando
- Croydon Health Services NHS TrustCódigo postal verificadoCroydon, United Kingdom· Aún no reclutando
- NHS Greater Glasgow and ClydeCódigo postal verificadoGlasgow, Reino Unido· Aún no reclutando
- The Leeds Teaching Hospitals NHS TrustCódigo postal verificadoLeeds, Reino Unido· Aún no reclutando
- The Clatterbridge Cancer Centre NHS Foundation TrustCódigo postal verificadoLiverpool, Reino Unido· Aún no reclutando
- Fundación Guy's y St Thomas' NHSCódigo postal verificadoLondres, Reino Unido· Aún no reclutando
Preguntas comunes
What is 'relapsed or refractory follicular lymphoma'?
It means your follicular lymphoma has either come back after treatment or hasn't responded well to previous treatments.
What does being 'randomised' mean?
It means you'll be randomly assigned by chance to receive either a new experimental treatment or one of the standard treatments, like flipping a coin.
How long will I be in the trial?
The active treatment phase could involve up to 12 cycles (about a year), followed by yearly check-ups for up to 10 years.
Can I stop participating if I want to?
Yes, you can withdraw from the trial at any time, and it won't affect your future medical care.
Will I know if I'm getting the new treatment or standard care?
Patients are typically informed about which arm of the trial they are assigned to, meaning you will know if you are receiving an experimental treatment or standard care.
Cómo obtener más información
Trial Coordinator
Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.
¿Interesado en participar?
Discusión
Discusión comunitaria
Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.